Clinipen, a game changing pen-based input device, has potential to accelerate EMR adoption
MARKHAM, ON, and LAS VEGAS, NV, Feb. 21, 2012 /CNW/ - Nightingale Informatix Corporation (TSXV: NGH) ("Nightingale" or the "Company", an application service provider (ASP) of Electronic Medical Record (EMR) software and related services and ExpeData, LLC ("ExpeData"), an innovative software company and global leader in digital writing, announced plans to launch "Clinipen", an EMR-integrated digital writing solution. Clinipen will be available in Canada in March 2012 and in the United States by August 2012.
Clinipen will enable EMR software providers to deliver an integrated digital writing solution that healthcare providers can use to input structured data into a patient's EMR directly from paper. The solution leverages the EDW® digital writing platform from ExpeData along with Anoto® digital pen and paper technology and Vision Objects' industry-leading handwriting recognition technologies. Nightingale's leading web-based EMR, Nightingale On Demand, will be the first solution seamlessly integrated with Clinipen.
"Nightingale is committed to innovation and making the transition from paper records to EMR as seamless as possible for physicians," said Sam Chebib, President and CEO of Nightingale. "We believe Clinipen is a major breakthrough in EMR data entry, as it allows healthcare providers to continue using paper forms to document patient encounters and write prescriptions. We believe integrating ExpeData's digital writing technology with Nightingale On Demand position both companies as clear technology leaders in the North American EMR market."
In Canada, it is estimated that more than 60% of physicians are still using paper-based records.1A recent independent survey conducted in the US indicated that only 34% of healthcare providers use a comprehensive EMR system, while 16% indicated using a partial system. 29% of respondents indicated that they are evaluating solutions, while 20% indicated that they have not yet started the adoption process. 2
"The seamless integration of the Clinipen digital writing technology with Nightingale On Demand provides healthcare providers with a familiar alternative to using a computer to input patient data into their EMR," said Brandon Major, Vice President and COO, ExpeData. "Unlike other digital pen products in the market place, Clinipen leverages the power of templates and intelligent handwriting recognition to allow users to continue to use paper as an input method, populating Nightingale's EMR with structured discrete data. We believe this will make the transition to EMR much more appealing to a large segment of Canadian and US healthcare providers."
In May 2011, Nightingale and ExpeData announced a joint venture agreement for exclusive distribution rights for the Clinipen technology products for the EMR industry in North America. Each company will maintain 50% ownership. Clinipen is the first product being launched as a result of the joint venture. ExpeData and Vision Objects are part of the digital writing investment portfolio held by Myrian Capital, a private equity firm focused on emerging technology businesses.
"Through this first Clinipen product, we are removing the obstacles to EMR adoption by making the solution user-friendly for those healthcare providers who continue to use handwritten paper-based records," said Paddy Padmanabhan, CEO of ExpeData and Managing Director of Myrian Capital. "They can now seamlessly transition to an EMR while maintaining the same processes across their healthcare organization. This provides groundbreaking potential to accelerate EMR adoption."
- 2009 Commonwealth Fund International Health Policy Survey of Primary Care Physicians
- 2nd Annual Healthcare IT Market: Insights and Opportunities Study, CompTIA, 2010
About Nightingale Informatix Corporation (http://www.nightingalemd.ca)
Nightingale is one of the fastest growing health care service and software companies in North America and is recognized as an industry leader in Web-based clinician and community based electronic medical records (EMR) and patient portals, serving the needs of small primary care practices, multi-physician outpatient clinics, and large scale regional health organizations and networks. Coupled with integrated practice management, transcription and revenue cycle management, Nightingale's comprehensive service offering allows customers to enhance patient care, increase revenue opportunities and optimize operations. Nightingale is continuously innovating and enhancing its services to meet the needs of its growing and diverse customer base. Nightingale - Healthcare connected.
About ExpeData, LLC
ExpeData is an innovative software company and a global leader in natural input technologies. ExpeData has created an end-to-end software platform that automates the collection of natural input including handwriting at the point of entry. Information captured with tablets or digital pens is immediately converted to digital data and seamlessly integrated to backend systems. Straight-through processing eliminates cycle time delays, resulting in unsurpassed workflow optimization and significant cost savings. EDW solutions are used across the globe, delivering value in multiple industries. To learn more, visit http://www.expedata.net.
Featuring Anoto Functionality The EDW® solutions are, in part, based on Anoto Digital Pen and Paper Technology, which is covered by over 200 patents worldwide, including but not limited to US6663008, US7172131, US7248250, US7281668, JP3872498, JP3842283, CN1595440, SE517445, RU2256225, and AU773011. "Anoto", "Magic Box" and the Anoto logotype are trademarks owned by Anoto AB.
Forward Looking Statement
This press release contains "forward-looking statements" respecting the issuance and cancellation of securities of the Company within the meaning of applicable Canadian securities legislation. Generally, forward-looking statements can be identified by the use of forward- looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may" ,"could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Nightingale to be materially different from those expressed or implied by such forward-looking statements, including but not limited to: risks related to the speculative nature of the medical software industry, which is affected by numerous factors beyond Nightingale's control; the ability of Nightingale to successfully integrate its acquisitions and any liabilities arising as a result of such acquisitions, access to capital and agreements with its Lenders; the existence of present and possible future government regulation; access to debt or equity financing and agreements with its Lenders; the significant and increasing competition that exists in the medical software industry; the early stage of Nightingale's business; and therefore it is subject to the risks associated with early stage companies, including uncertainty of revenues, markets and profitability and the need to raise additional funding. All material assumptions used in making forward-looking statements are based on management's knowledge of current business conditions and expectations of future business conditions and trends. Although management believes the assumptions used to make such statements are reasonable at this time, our assumptions may not to be as anticipated, estimated or intended. Certain material factors or assumptions applied by management in making forward-looking statements, include without limitation, factors and assumptions regarding Nightingale's continued ability to fund its business, rates of customer defaults, relationships with, and payments to, lenders, demand for Nightingale's products, as well as Nightingale's operating cost structure.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information:
Kristen Dickson, M.Sc.
Equicom, a TMX Group Company
Tel: 416.815.0700 ext. 273
Director, Marketing and Corporate Communications